

PROVIDER QUICK POINTS

PROVIDER INFORMATION



August 28, 2024

Commercial Pharmacy Benefit Exclusion for edaravone, Kisunla™, PiaSky®, and Tecelra®

Effective **August 28, 2024**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
edaravone injection solution for intravenous (IV) infusion
Kisunla™ (donanemab-azbt) solution for intravenous (IV) infusion
PiaSky® (crovalimab-akkz) solution for intravenous (IV) infusion and subcutaneous (SC) injection
Tecelra® (afamitresgene autoleucel) solution for intravenous (IV) infusion

Products Impacted

These exclusions apply to commercial lines of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.